This public-private partnership seeks to develop new ways of identifying and validating promising biological targets for diagnostics and drug development.
Led by Dr. Mariana Kaplan, the branch studies autoimmune diseases, like lupus and rheumatoid arthritis, seeking treatments and improved outcomes.
Led by Dr. Timothy Bhattacharyya, the unit investigates orthopedic conditions, including femur fractures and hip infections, and related treatments.
Led by Dr. Vittorio Sartorelli, the lab studies mechanisms that regulate specification, differentiation, and regeneration of skeletal muscle cells.
What is ichthyosis? Ichthyosis is a group of skin disorders. It leads to dry, itchy skin that appears scaly, rough, and red. The symptoms can range from mild to severe. Ichthyosis can affect only the skin, but sometimes the disease can affect internal organs, too.
Research supported by the Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) provides new insights into tissue damage for these autoimmune conditions. Findings include the identification of novel molecular signatures related to immune system signaling in kidney cells that may reflect their active role in disease process; molecular targets, including specific white blood cells, for potential treatment in lupus nephritis; and specific types of fibroblasts and white blood cells that are involved in rheumatoid arthritis.
A type of skin cell called a dermal fibroblast can make an antimicrobial compound called cathelicidin in response to infection by acne-causing bacteria.
Human skin is home to diverse ecosystems including bacteria, viruses, and fungi. These microbial communities comprise hundreds of species and are collectively known as the skin microbiome.